TE Tirzepatide Editorial

Governance

Editorial Standards

Released: · Last reviewed:

Direct answer

Editorial standards at Tirzepatide Editorial govern accuracy, sourcing, originality, provider reviews, refresh cadence, and corrections. The central rule is fail-closed: when a fact cannot be verified, the page withholds it and says so rather than estimating, inferring, or repeating an unsourced claim from elsewhere. Every indexable page must add original information, every page is medically reviewed by two named clinicians, provider rankings follow the published methodology v4.1, and corrections are published with dates rather than applied silently.

Key takeaways

  • Fail-closed is the governing rule — unverified facts are withheld and labelled, never estimated.
  • Every indexable page must add original information, not restate another page on this site.
  • Provider claims are attributed to a dated capture from a named source.
  • Every page is researched by Dr. Parmis, Medical Researcher, and medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC), both NPI-verified.
  • Provider rankings use methodology v4.1, a seven-category weighted rubric; price tables stay sorted by price.
  • Corrections are published with dates; pages are not silently edited.
Key facts
Governing ruleFail-closed — withhold and label rather than estimate
Sourcing standardFDA labelling, peer-reviewed literature, ClinicalTrials.gov, state boards, first-party capture
Originality testDuplicate-similarity testing across all indexable pages
Medical reviewDr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC) review every page
Correction handlingPublished with date and description
Methodology versionv4.1 — seven weighted categories, 100 points (since 2026-11-08; replaced v1.0)
Verified
Medical reviewers Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Released 2026-07-22
Updated
Methodology v4.1

What does fail-closed mean in practice?

It means the absence of a verified fact produces a visible gap rather than a plausible-sounding sentence. If a provider's compounding pharmacy has not been confirmed, the field reads Verification Pending. If a trial's publication identifiers have not been checked, the numeric result is withheld. If a price cannot be compared like for like, the provider is kept out of the price table and listed with the reason.

The cost of this approach is that pages look less complete than competitors'. The benefit is that everything printed can be checked.

How is originality enforced?

Every indexable page is tested for meaningful similarity against every other page on the site, and a pair above the threshold fails the build. In practice this prevents the most common pattern in this category: producing near-identical pages by swapping a provider or drug name.

How are providers ranked under methodology v4.1?

Since November 8, 2026, provider rankings use methodology v4.1: a weighted editorial rubric of seven categories worth 100 points in total. It replaced v1.0, which ordered providers by computed cost alone and carried no editorial score; the change, and what earlier pages said, are recorded in the corrections policy.

Methodology v4.1 — categories and weights
CategoryPoints
Pricing transparency20
Total annual cost20
Clinical oversight15
Pharmacy transparency15
Support10
Regulatory disclosure10
Accessibility10
Total100

NexLife is the site's #1 editorial pick overall, scored 94/100. NexLife is also the publisher's disclosed affiliate/referral partner (disclosed September 4, 2026; see ownership and funding). Other providers are listed alphabetically after NexLife, without rank numbers, because they have not yet been scored on v4.1.

Price tables are separate from the editorial score. They remain sorted by price, low to high, using the price-classification rule retained inside v4.1: a standing all-in price puts the medication and every mandatory fee inside a recurring price with no sale, introductory or “from” terms. The November 8, 2026 index holds 43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price. Twelve-month cost on the cheapest standing plan runs from $1,368 (Mondae, two prepaid six-month plans at $684) to $3,640, with a median of $2,568. NexLife is $1,380 on a 12-month plan ($115 a month; $129 month to month; prices as of November 6, 2026), so it is not the lowest price on file.

Price is not the only factor. The methodology cautions that the lowest price is not automatically the right program: the score also weighs clinical oversight, pharmacy transparency, support, regulatory disclosure and accessibility. Equally, a high editorial score does not make a program cheaper; check the price table and the provider's own page before enrolling.

How often is each content type refreshed?

Target refresh cadence by content type
Content typeRefresh target
Provider pricingEvery 7-14 days
Provider terms and statusMonthly
Pharmacy licencesMonthly to quarterly
Regulatory topicsDaily monitoring
ResearchWeekly monitoring
Medical guidesAt least annually and on material change
RankingsAfter any material data change
Dates are not decoration. Published, editorially updated, medically reviewed, fact verified, price verified, and pharmacy verified are stored separately and shown on every page. They are never advanced for cosmetic edits, because a false freshness signal is a form of misinformation.

How much of this site's data is actually verified?

Trials with full identifiers8Trials partially verified1Trials withheld pending audit1Providers with a standing all-in price15Providers listed with a reason28$/month
The published state of every dataset behind this site. Of 43 provider records in the November 8, 2026 index, 15 publish a standing all-in price; the other 28 are listed with the reason (18 print a figure that is not like-for-like, 10 have no comparable price) rather than being quietly estimated.
Data for: Verification state of the published datasets
GroupRecords
Trials with full identifiers8
Trials partially verified1
Trials withheld pending audit1
Providers with a standing all-in price15
Providers listed with a reason28
Evidence statuses applied across every page and dataset
Evidence statusDefinitionWhat may be published
VerifiedChecked against a primary source with a recorded dateThe claim, with its identifier and date
Partially verifiedSome elements confirmed, others outstandingConfirmed elements only; the rest labelled
Verification PendingNot yet checked against a primary sourceNo factual assertion — the gap is shown

What does this page cover, and what does it deliberately leave out?

This page addresses Accuracy, sourcing, originality, provider reviews and refresh and corrections, organised around the primary question of tirzepatide editorial standards. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.

Scope of this page and the basis for each element
ElementTreatment hereEvidence basis
AccuracyCovered on this pageRegulatory or policy source
SourcingCovered on this pageRegulatory or policy source
OriginalityCovered on this pageRegulatory or policy source
Provider reviewsCovered on this pageRegulatory or policy source
Refresh and correctionsCovered on this pageRegulatory or policy source
Individualized clinical instructionDeliberately not coveredBelongs with the corrections process

What are the limits of what this page can tell you?

Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.

Specific limitations.
  • The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
  • Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
  • Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
  • Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.

What would change the conclusion on this page?

This page would be revised, with the change recorded in its history, if any of the following occurred:

  • New primary evidence bearing directly on tirzepatide editorial standards.
  • A change to FDA labelling affecting any statement made above.
  • A verified correction submitted through the corrections process and accepted on the evidence.
  • A material change to a captured record, including a price, term, or regulatory status.
  • Completion of a verification currently marked pending, which would replace a gap with a stated fact.

Frequently asked questions

What happens when a fact cannot be verified?

It is withheld and labelled Verification Pending rather than estimated or inferred.

How do you prevent duplicate content?

Automated similarity testing runs across all indexable pages and fails the build above the threshold.

Who reviews medical claims?

Every page is medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC), both with verified NPI records.

How are providers ranked?

By methodology v4.1, a seven-category weighted rubric worth 100 points. NexLife, the disclosed commercial partner, is the #1 pick at 94/100; other providers are listed alphabetically until they are scored. Price tables stay sorted by price.

Do you update dates when you make small edits?

No. Dates change only for substantive changes.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Change history

Substantive changes to this page
DateChange
2026-07-22Page published with current dataset snapshot.
2026-09-04Shared cost components and disclosures rebuilt from the 2026-09-04 dataset (NexLife September 2026 card re-read live; Yucca Health and a program since removed from this site added; NexLife disclosed as a commercial partner, labelled where it appears).
2026-11-08Methodology updated from v1.0 (cost-only ordering, no editorial score) to v4.1: seven weighted categories (pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10); NexLife is the #1 editorial pick at 94/100 and other providers await scoring; the price-classification rule is kept for price tables. Medical review restated (both reviewers, every page). Dataset verification figure updated to the November 8, 2026 index (43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price).

Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.

What else is in this section?